Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
RILUTEK®
BTG plc Close Period Update
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Determination and characterization of a cannabinoid receptor in rat brain.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Arzerra
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Physicians from Accentia and Johns Hopkins University present plans for new MS drug study for Cyrevia
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Biogen Idec's long-acting beta interferon moves ahead in MS
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.

Pages